Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 83,334 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $23.57, for a total transaction of $1,964,182.38. Following the sale, the chief executive officer now directly owns 235,838 shares in the company, valued at $5,558,701.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Nektar Therapeutics (NASDAQ NKTR) traded down $0.56 during midday trading on Friday, hitting $23.53. 731,900 shares of the stock were exchanged, compared to its average volume of 1,063,695.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.04). Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The company had revenue of $34.60 million during the quarter, compared to analyst estimates of $33.64 million. During the same period last year, the company posted ($0.36) earnings per share. The company’s revenue was up 5.5% compared to the same quarter last year. equities research analysts predict that Nektar Therapeutics will post -0.95 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/03/nektar-therapeutics-nktr-ceo-sells-1964182-38-in-stock.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA increased its stake in shares of Nektar Therapeutics by 38.0% in the third quarter. BNP Paribas Arbitrage SA now owns 112,584 shares of the biopharmaceutical company’s stock worth $2,702,000 after acquiring an additional 30,985 shares during the last quarter. Alps Advisors Inc. increased its stake in shares of Nektar Therapeutics by 9.9% in the third quarter. Alps Advisors Inc. now owns 153,958 shares of the biopharmaceutical company’s stock worth $3,695,000 after acquiring an additional 13,915 shares during the last quarter. Candriam Luxembourg S.C.A. increased its stake in shares of Nektar Therapeutics by 12.5% in the third quarter. Candriam Luxembourg S.C.A. now owns 259,900 shares of the biopharmaceutical company’s stock worth $6,238,000 after acquiring an additional 28,900 shares during the last quarter. Swiss National Bank increased its stake in shares of Nektar Therapeutics by 1.4% in the third quarter. Swiss National Bank now owns 259,500 shares of the biopharmaceutical company’s stock worth $6,228,000 after acquiring an additional 3,700 shares during the last quarter. Finally, Tocqueville Asset Management L.P. increased its stake in shares of Nektar Therapeutics by 8.5% in the third quarter. Tocqueville Asset Management L.P. now owns 252,202 shares of the biopharmaceutical company’s stock worth $6,053,000 after acquiring an additional 19,800 shares during the last quarter. 95.13% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have issued reports on NKTR. Jefferies Group LLC reissued a “buy” rating and set a $23.00 target price on shares of Nektar Therapeutics in a research note on Friday, July 21st. Roth Capital set a $33.00 target price on shares of Nektar Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 9th. BidaskClub downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Evercore ISI began coverage on shares of Nektar Therapeutics in a research note on Thursday, August 17th. They set an “in-line” rating and a $20.00 target price on the stock. Finally, William Blair reissued an “outperform” rating on shares of Nektar Therapeutics in a research note on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $26.80.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.